Hikma Pharmaceuticals Plc Stock Shares Owned By Insiders
| HKMPY Stock | USD 50.32 0.51 1.02% |
Hikma Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Hikma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Hikma Pink Sheet. The fundamental analysis module provides a way to measure Hikma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hikma Pharmaceuticals pink sheet.
Hikma |
Hikma Pharmaceuticals PLC Company Shares Owned By Insiders Analysis
Hikma Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 0.0% of Hikma Pharmaceuticals PLC are shares owned by insiders. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The shares owned by insiders for all United States stocks is 100.0% higher than that of the company.
Hikma Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hikma Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hikma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Hikma Pharmaceuticals by comparing valuation metrics of similar companies.Hikma Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Hikma Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 110.13 M | |||
| Price To Earning | 10.10 X | |||
| Price To Book | 1.89 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 2.55 B | |||
| Gross Profit | 1.3 B | |||
| EBITDA | 759 M | |||
| Net Income | 421 M | |||
| Cash And Equivalents | 393 M | |||
| Cash Per Share | 3.57 X | |||
| Total Debt | 651 M | |||
| Debt To Equity | 0.71 % | |||
| Current Ratio | 2.12 X | |||
| Book Value Per Share | 19.77 X | |||
| Cash Flow From Operations | 638 M | |||
| Earnings Per Share | 2.99 X | |||
| Price To Earnings To Growth | 2.41 X | |||
| Number Of Employees | 8.7 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 4.72 B | |||
| Total Asset | 4.37 B | |||
| Retained Earnings | 1.16 B | |||
| Working Capital | 701 M | |||
| Current Asset | 1.57 B | |||
| Current Liabilities | 866 M | |||
| Z Score | 4.2 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 1.79 % | |||
| Net Asset | 4.37 B | |||
| Last Dividend Paid | 0.55 |
About Hikma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hikma Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hikma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hikma Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hikma Pink Sheet Analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.